Drugs / riferminogene pecaplasmid
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01157143 | Jan 2002 → Oct 2003 | peripheral arterial occlusive disease 1 | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01157156 | Jun 1999 → Sep 2001 | peripheral arterial occlusive disease 1 | Sanofi | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT01157871 | Jun 2004 → Aug 2005 | peripheral arterial occlusive disease 1 | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00798005 | Jun 2002 → Jul 2005 | peripheral arterial occlusive disease 1 | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00368797 | Mar 2002 → Apr 2005 | peripheral arterial disease | Sanofi | Completed | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00566657 | Nov 2007 → Aug 2010 | peripheral vascular disease | Sanofi | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | riferminogene pecaplasmid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00566657 ↗ |
| Known as | NV1FGF | “This four center peripheral artery disease registry was designed to evaluate the long-term safety of the intramuscular non-viral fibroblast growth factor-1 (NV1FGF), a...” PMID 21716303 ↗ Jun 2011 |
| Known as | Riferminogen pecaplasmido | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108293 ↗ |
| Known as | XRP0038 | “XRP0038 (NV1FGF)” NCT00368797 ↗ |
| Modality | Other / unclassified | “a plasmid-based angiogenic gene delivery system” PMID 18388929 ↗ Apr 2008 |
| Route | Intramuscular | “intramuscular administration of NV1FGF” PMID 18388929 ↗ Apr 2008 |
| Target | FGF1 | “a plasmid-based angiogenic gene for local expression of fibroblast growth factor-1” PMID 21716303 ↗ Jun 2011 |